Literature DB >> 8615041

The production of recombinant infectious DI-particles of a murine coronavirus in the absence of helper virus.

E C Bos1, W Luytjes, H V van der Meulen, H K Koerten, W J Spaan.   

Abstract

We have studied the production and release of infectious DI-particles in vaccinia-T7-polymerase recombinant virus-infected L cells that were transfected with five different plasmids expressing the synthetic DI RNA MIDI-HD and the four structural proteins (M, N, S, and E) of the murine coronavirus MHV-A59. The DI cDNA contains the hepatitis delta ribozyme sequences to generate in the transfected cells a defined 3' end. In EM studies of transfected cells virus-like particles (VLP) were observed in vesicles. Release of the particles into the medium was studied by immunoprecipitations of proteins released into the culture supernatant. Particle release was independent of S or N, but required M and E. Coexpression of E and M was sufficient for particle release. Coexpression of the structural proteins and the MIDI-HD RNA resulted in the production and release of infectious DI-particles. Infectivity of the DI-particles was determined by adding helper virus MHV-A59 to the medium containing the VLPs and using this mixture to infect new L cells. Intracellular RNA of several subsequent undiluted passages was isolated to detect the MIDI-HD RNA. Passage of the MIDI-HD RNA was dependent on the expression of the structural proteins of MHV-A59 in the transfected cells. In the absence of either E or M, MIDI-HD RNA could not be passaged to fresh L cells. We have thus developed a system in which we can produce coronavirus-like particles and an assay to test their infectivity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8615041      PMCID: PMC7130547          DOI: 10.1006/viro.1996.0165

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  114 in total

1.  Mapping of the coronavirus membrane protein domains involved in interaction with the spike protein.

Authors:  C A de Haan; M Smeets; F Vernooij; H Vennema; P J Rottier
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

2.  Assembly of the coronavirus envelope: homotypic interactions between the M proteins.

Authors:  C A de Haan; H Vennema; P J Rottier
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

3.  Evolved variants of the membrane protein can partially replace the envelope protein in murine coronavirus assembly.

Authors:  Lili Kuo; Paul S Masters
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

4.  Membrane topology of coronavirus E protein.

Authors:  J Maeda; J F Repass; A Maeda; S Makino
Journal:  Virology       Date:  2001-03-15       Impact factor: 3.616

5.  Characterization of the coronavirus M protein and nucleocapsid interaction in infected cells.

Authors:  K Narayanan; A Maeda; J Maeda; S Makino
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

6.  The coronavirus spike protein induces endoplasmic reticulum stress and upregulation of intracellular chemokine mRNA concentrations.

Authors:  Gijs A Versteeg; Paula S van de Nes; Peter J Bredenbeek; Willy J M Spaan
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

Review 7.  The molecular biology of coronaviruses.

Authors:  Paul S Masters
Journal:  Adv Virus Res       Date:  2006       Impact factor: 9.937

8.  Role of the coronavirus E viroporin protein transmembrane domain in virus assembly.

Authors:  Ye Ye; Brenda G Hogue
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

9.  Suppression of coronavirus replication by inhibition of the MEK signaling pathway.

Authors:  Yingyun Cai; Yin Liu; Xuming Zhang
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

10.  Genetic analysis of determinants for spike glycoprotein assembly into murine coronavirus virions: distinct roles for charge-rich and cysteine-rich regions of the endodomain.

Authors:  Rong Ye; Cynthia Montalto-Morrison; Paul S Masters
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.